Severe cutaneous adverse reactions including SJS & DRESS. Discontinue immediately if myopathy is suspected. Treatment should not be started if repeat test confirms baseline creatine kinase >5x ULN. Patients w/ pre-disposing factors for myopathy/rhabdomyolysis including renal impairment, hypothyroidism, personal or family history of hereditary muscular disorders, previous history of muscular toxicity w/ another HMG-CoA reductase inhibitor or fibrate, alcohol abuse, situations where an increase in plasma levels may occur, concomitant use of fibrates. Immune-mediated necrotizing myopathy (rarely). Concomitant use w/ gemfibrozil or PIs is not recommended. Concomitant use w/ fibrates or niacin; anticoagulants (eg, warfarin, another coumarin anticoagulant, or fluindione. Do not use in patient w/ an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders, or uncontrolled seizures). Must not be co-administered w/ systemic formulations of fusidic acid or w/in 7 days of stopping treatment. LFT should be carried out prior to, & 3 mth following the initiation of rosuvastatin treatment. Patients w/ secondary hypercholesterolemia caused by hypothyroidism or nephrotic syndrome. ILD (long-term therapy). DM. Patients who consume excessive quantities of alcohol &/or have a history of liver disease. Dizziness may occur which may affect ability to drive & use machines. Not recommended in patients w/ moderate or severe hepatic insufficiency. Asians. Childn. Elderly >70 yr.
Sign Out
